Nwam LLC Has $1.84 Million Stake in Pfizer, Inc. (PFE)
Nwam LLC raised its position in Pfizer, Inc. (NYSE:PFE) by 5.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 53,786 shares of the biopharmaceutical company’s stock after buying an additional 2,699 shares during the period. Nwam LLC’s holdings in Pfizer were worth $1,840,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Asset Planning Services Ltd. raised its position in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the period. Orrstown Financial Services Inc. raised its position in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the period. Cable Hill Partners LLC raised its position in shares of Pfizer by 6.0% in the first quarter. Cable Hill Partners LLC now owns 4,664 shares of the biopharmaceutical company’s stock worth $160,000 after buying an additional 265 shares during the period. Acropolis Investment Management LLC raised its position in shares of Pfizer by 1.9% in the first quarter. Acropolis Investment Management LLC now owns 5,251 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 100 shares during the period. Finally, Cohen Lawrence B acquired a new position in shares of Pfizer during the first quarter worth about $201,000. Institutional investors own 69.09% of the company’s stock.
Shares of Pfizer, Inc. (NYSE PFE) traded down 0.254% during midday trading on Tuesday, hitting $33.385. The stock had a trading volume of 2,827,482 shares. Pfizer, Inc. has a one year low of $29.83 and a one year high of $35.18. The firm has a market capitalization of $198.55 billion, a PE ratio of 24.422 and a beta of 1.00. The firm’s 50-day moving average price is $33.25 and its 200-day moving average price is $33.42.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the business posted $0.64 EPS. The business’s revenue was down 1.9% compared to the same quarter last year. On average, equities analysts predict that Pfizer, Inc. will post $2.56 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a yield of 3.82%. Pfizer’s payout ratio is currently 94.12%.
A number of research analysts have issued reports on the company. Berenberg Bank reiterated a “hold” rating and set a $36.00 price target (down previously from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, August 24th. BidaskClub upgraded Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Cowen and Company set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Finally, UBS AG reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $37.61.
In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of the stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the sale, the insider now directly owns 74,506 shares in the company, valued at approximately $2,436,346.20. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now owns 151,474 shares of the company’s stock, valued at $5,074,379. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 120,014 shares of company stock valued at $4,062,493. Company insiders own 0.06% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.